viral
infect
remain
major
worldwid
caus
morbid
mortal
among
aggress
viral
infect
ebola
aid
acquir
immunodefici
syndrom
influenza
sar
sever
acut
respiratori
syndrom
instanc
influenza
respons
million
new
case
sever
diseas
death
yearli
alarmingli
number
patient
diagnos
viral
infect
increas
everi
year
blood
transfus
organ
transplant
use
hypoderm
syring
classic
antivir
drug
interferon
ribavirin
effect
vitro
virus
often
ineffect
patient
nineti
differ
antivir
agent
avail
today
treat
select
virus
virus
includ
hiv
human
immunodefici
viru
herp
virus
includ
hsv
herp
simplex
viru
hcmv
human
cytomegaloviru
vzv
varicella
zoster
viru
influenza
virus
hepat
virus
fig
current
approv
remedi
mani
type
virus
vaccin
limit
hepat
viru
mump
varicella
addit
agent
often
costli
ineffect
due
viral
resist
caus
side
effect
mind
natur
base
pharmacotherapi
may
proper
altern
treat
viral
diseas
thu
necessari
examin
topic
antivir
phytochem
highlight
drug
deliveri
applic
overcom
multipl
biolog
barrier
exist
antivir
agent
success
reach
intend
site
action
present
review
focus
antivir
properti
herb
extract
bioactiv
constitu
isol
medicin
plant
effort
obtain
effici
deliveri
variou
plant
use
medicin
sinc
ancient
time
known
strong
therapeut
effect
tradit
medicin
diseas
possibl
viral
origin
treat
mani
plant
main
find
relat
antivir
plant
extract
collect
tabl
includ
extract
test
cell
cultur
extract
also
studi
vivo
variou
phytochem
isol
purifi
identifi
crude
extract
alkaloid
terpen
flavonoid
variou
glycosid
protein
tabl
compound
antivir
activ
present
mani
plant
eg
rutin
flavonoid
glycosid
common
differ
plant
effect
avian
influenza
viru
viru
quercetin
aglycon
rutin
phytochem
abund
plant
may
diminish
replic
mani
virus
highli
pathogen
influenza
viru
rhinoviru
dengu
viru
polioviru
adenoviru
epsteinbarr
viru
mayaro
viru
japanes
enceph
viru
respiratori
syncyti
viru
hcv
antivir
activ
mode
studi
case
abil
inhibit
hcv
limit
activ
heat
shock
protein
hsp
produc
cell
respons
exposur
stress
involv
nonstructur
protein
mediat
viral
ire
intern
ribosom
entri
site
translat
one
wellknown
mechan
anoth
mechan
involv
inhibit
hcv
proteas
hcv
replic
subgenom
hcv
rna
replicon
cell
system
quercetin
also
inhibit
variou
step
rhinovirus
pathogenesi
ie
endocytosi
viral
genom
transcript
protein
synthesi
anoth
case
quercetin
shown
specif
mode
action
reduc
replic
dengu
viru
process
viral
attach
entri
addit
quercetin
three
flavonoid
myricetin
quercetagetin
baicalein
effect
inhibit
revers
transcriptas
rauscher
murin
leukemia
viru
rlv
hiv
quercetin
myricetin
quercetagetin
also
shown
inhibit
differ
dna
polymeras
enzym
abovement
flavonoid
myricetin
abund
wild
plant
nut
fruit
berri
veget
ellag
acid
myricetin
aronia
fruit
activ
cell
cultur
differ
subtyp
influenza
virus
includ
oseltamivirresist
strain
also
effect
vivo
apigenin
aglycon
flavon
class
found
mani
plant
broad
antivir
activ
foot
mouth
diseas
viru
hcv
african
swine
fever
viru
asfv
influenza
viru
note
mani
flavonoid
plant
origin
known
antivir
properti
exampl
differ
flavonoid
six
phytochem
apigenin
baicalein
biochanin
kaempferol
luteolin
naringenin
activ
avian
influenza
viru
human
lung
epitheli
cell
inhibit
nucleoprotein
product
baicalin
glucuronid
baicalein
also
activ
wide
rang
virus
includ
enteroviru
dengu
viru
respiratori
syncyti
viru
newcastl
diseas
viru
human
immunodefici
viru
hepat
b
viru
differ
mechan
suggest
antivir
action
exampl
baicalin
inhibit
product
hbv
templat
viral
protein
hbvdna
synthesi
decreas
product
without
affect
level
shown
studi
avian
influenza
viru
triterpenoid
oleanol
acid
ursol
acid
abund
plant
kingdom
may
effect
hcv
reduc
hcv
rdrp
virul
also
inhibit
enteroviru
replic
lastli
sambucu
nigra
l
activ
ingredi
standard
elderberri
extract
effect
use
treatment
fever
cold
influenza
b
introduc
pharmaceut
nanotechnolog
field
natur
medicin
use
promis
new
strategi
deliveri
poorli
solubl
phytochem
plant
extract
allow
improv
pharmacokinet
clinic
outcom
commonli
use
approach
phytosom
nanoparticl
hydrogel
microspher
transferosom
ethosom
selfmicroemulsifi
drug
deliveri
system
smedd
selfnanoemulsifi
drug
deliveri
system
snedd
appli
deliveri
antivir
plant
agent
tabl
antivir
technolog
may
prefer
older
phytochem
drug
formul
due
enhanc
solubl
oral
absorpt
system
bioavail
safeti
delay
metabol
better
overal
antivir
activ
yet
paper
publish
topic
antivir
herbal
drug
deliveri
wish
display
sever
success
attempt
improv
deliveri
phytodrug
known
antivir
activ
qian
et
al
attempt
design
selfnanoemulsifi
drug
deliveri
system
snedd
allow
greater
appar
solubl
oral
bioavail
myricetin
overal
four
formul
prepar
capryol
rh
ratio
capryol
rh
capryol
eltranscutol
hp
capryol
rh
hp
solubl
myricetin
differ
excipi
studi
optim
formul
underw
evalu
releas
dissolut
cell
cytotox
intestin
permeabl
studi
vitro
follow
vivo
pharmacokinet
myricetinsnedd
three
four
chosen
formul
exhibit
accept
cell
viabil
fourth
formul
slightli
celltox
probabl
high
nonion
surfact
content
vitro
drug
releas
test
demonstr
myricetin
alon
limit
dissolut
hour
wherea
drug
releas
snedd
formul
min
singlepass
intestin
perfus
spip
method
rat
show
duodenum
primari
absorpt
site
myricetin
effect
permeabl
coeffici
significantli
higher
p
snedd
formul
rel
free
myricetin
via
inhibit
myricetin
efflux
nonion
surfact
snedd
fig
anim
model
myricetinload
snedd
formul
exhibit
higher
plasma
myricetin
concentr
time
point
compar
free
myricetin
formul
fig
higher
intestin
permeabl
show
lower
bioavail
attribut
poor
lymphat
main
absorpt
mechan
myricetin
formul
hand
achiev
small
particl
size
requir
lymphat
transport
fig
kim
et
al
tri
increas
oral
bioavail
low
solubl
flavonoid
apigenin
differ
waterinoilinwat
emuls
apigenin
studi
physic
characterist
well
digest
use
vitro
digest
model
vivo
pharmacokinet
rat
emuls
soybean
oiltween
chosen
pharmacokinet
test
anim
model
prove
better
stabil
term
particl
size
zeta
potenti
plasma
concentr
apigenin
waterinoil
emuls
markedli
higher
differ
time
point
maxim
concentr
higher
compar
apigenin
suspens
zhang
et
al
aim
improv
oral
absorpt
baicalin
low
solubl
poor
permeabl
use
micellar
formul
compris
carrier
pluron
copolym
sodium
taurochol
sustain
releas
profil
baicalinload
mix
micel
vitro
drug
releas
experi
held
sever
ph
condit
show
drug
releas
h
gastric
condit
releas
within
h
intestin
condit
compar
releas
baicalin
suspens
respect
observ
suggest
improv
stabil
afford
design
formul
vitro
uptak
studi
carri
cell
line
determin
absorpt
baicalin
within
mix
micel
verifi
intern
abil
baicalinload
formul
achiev
high
oral
bioavail
fig
result
believ
deriv
micellar
small
size
pluron
compon
pglycoprotein
inhibitor
addit
mix
micel
formul
show
bimod
present
presum
attribut
enterohepat
recircul
enhanc
drug
oral
bioavail
oleanol
acid
low
aqueou
solubl
system
bioavail
rat
smedd
develop
attempt
overcom
limit
deliveri
system
consist
ethyl
oleat
oil
cremophor
el
surfact
alcohol
cosurfact
allow
great
increas
oleanol
acid
solubl
vitro
studi
show
sustain
releas
behavior
smedd
system
rat
bioavail
significantli
higher
smedd
market
tablet
oleanol
acid
fig
improv
drug
oral
bioavail
explain
enhanc
solubl
permeabl
emulsif
small
particl
size
respect
flo
lonicera
japonica
fructu
forsythia
use
togeth
chines
herbal
remedi
antivir
antibacteri
antiinflammatori
properti
attempt
made
enhanc
bioavail
antiinfluenza
properti
herb
combin
chitooligosaccharid
chitosan
deriv
cell
cultur
antiinfluenza
assay
chitooligosaccharid
improv
activ
extract
contain
flo
lonicera
japonica
fructu
forsythia
compar
extract
contain
chitooligosaccharid
absorpt
studi
vitro
use
model
higher
experiment
deriv
appar
permeabl
valu
obtain
increas
concentr
chitooligosaccharid
vivo
pharmacokinet
show
signific
increas
flo
lonicera
japonica
fructu
forsythia
concentr
codeliv
chitooligosaccharid
rel
herb
administr
alon
fig
addit
enhanc
antivir
effect
achiev
four
prepar
contain
chitooligosaccharid
explain
higher
absorpt
caffeic
acid
deriv
fig
work
uniqu
studi
effect
deliveri
system
pharmacokinet
properti
antivir
activ
herbal
drug
directli
inclus
complex
honokiol
sulfobutyl
made
enhanc
solubl
bioavail
herbal
drug
phase
solubl
experi
honokiol
solubl
linearli
increas
grow
level
cyclodextrin
vitro
releas
studi
show
honokiolcyclodextrin
complex
allow
enhanc
releas
rate
either
honokiolcyclodextrin
physic
mixtur
honokiol
alon
rat
oral
pharmacokinet
auc
cmax
valu
inclus
complex
time
higher
rel
honokiol
suspens
respect
also
honokiol
suspens
time
higher
bodi
clearanc
complex
honokiol
andrographolid
sparingli
solubl
water
unstabl
acid
basic
condit
poorli
absorb
low
oral
bioavail
plga
poli
lacticcoglycol
acid
use
form
andrographolid
load
microspher
overcom
limit
vitro
andrographolidemicrospher
formul
exhibit
sustain
releas
profil
day
andrographolid
releas
first
h
low
drug
densiti
surfac
deliveri
system
also
allow
rel
high
oral
bioavail
lastli
fine
correl
obtain
vitro
drug
releas
vivo
absorpt
indic
vitro
assay
may
good
predictor
drug
absorpt
vivo
curcumin
polyphenol
compound
variou
medic
applic
includ
known
antiviru
activ
poorli
watersolubl
low
oral
bioavail
nacetyl
lcystein
differ
level
mg
polyethylen
glycol
peg
nanostructur
solid
lipid
carrier
synthes
obtain
curcumin
mucoadhes
mucu
penetr
drug
releas
character
vitro
curcumin
solut
curcuminload
nanolipid
carrier
curcuminload
nanolipid
carrier
nacetyl
lcystein
peg
curcumin
solut
drug
releas
h
wherea
nanolipid
formul
allow
sustain
curcumin
releas
sustain
releas
effect
modifi
nanolipid
carrier
pronounc
unmodifi
nanolipid
spip
studi
rat
conduct
result
similar
three
part
small
intestin
nanolipid
allow
enhanc
curcumin
permeat
rel
solut
higher
nacetyl
lcystein
content
pharmacokinet
studi
curcumin
solut
po
iv
curcumin
nanolipid
carrier
nacetyl
lcystein
peg
content
mg
conduct
similar
result
permeabl
experi
plasma
curcumin
concentr
higher
nanolipid
carrier
rel
solut
either
po
iv
increas
higher
nacetyl
lcystein
peg
level
area
curv
substanti
larger
modifi
nanolipid
carrier
compar
either
curcumin
solut
unmodifi
deliveri
system
inde
modern
drug
deliveri
technolog
numer
tailor
appropri
formul
medicin
phytochem
question
matter
trial
error
rather
physicochem
properti
specif
natur
drug
substanc
determin
deliveri
issu
formul
may
face
excipi
use
overcom
challeng
among
physicochem
properti
import
log
p
measur
drug
lipophil
melt
point
paramet
determin
likelihood
activ
substanc
precipit
gastrointestin
lumen
case
use
amorph
formul
may
prefer
oral
carrier
addit
import
physicochem
properti
includ
drug
chemic
structur
molecular
weight
use
previous
success
formul
deliv
drug
similar
chemic
structur
may
wise
approach
also
gener
speak
higher
molecular
weight
substanc
may
better
incorpor
lipidbas
drug
deliveri
system
note
solubilityen
formul
may
simultan
decreas
drug
permeabl
overal
absorpt
may
unimprov
solubilityperm
interplay
shown
formul
base
cyclodextrin
surfact
cosolv
hydrotrop
amorph
solid
dispers
asd
hand
solubl
increas
via
supersatur
unchang
permeabl
thu
asd
may
prefer
carrier
system
given
supersatur
achiev
maintain
suffici
time
altogeth
evid
present
work
support
notion
medicin
plant
promis
therapeut
potenti
especi
case
herb
product
viral
infect
research
mechan
phytochem
exhibit
antivir
effect
allow
develop
success
targetspecif
drug
deliveri
system
moment
ensur
plant
phytochem
directli
reach
virus
correct
structur
insid
cell
ideal
would
smart
pharmaceut
nanotechnolog
target
strategi
avoid
cellular
defens
transport
drug
target
intracellular
site
releas
drug
respons
specif
molecular
signal
literatur
also
lack
random
clinic
trial
discern
strength
new
herbal
antivir
drug
deliveri
system
hope
futur
high
qualiti
clinic
relev
studi
accumul
literatur
shed
light
full
potenti
phytochem
novel
antivir
agent
adequ
deliveri
system
